Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
GRIN2A Antibody (C-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | Q12879 |
|---|---|
| Clone Names | 81201054 |
| Gene ID | 2903 |
|---|---|
| Other Names | Glutamate receptor ionotropic, NMDA 2A, GluN2A, Glutamate [NMDA] receptor subunit epsilon-1, N-methyl D-aspartate receptor subtype 2A, NMDAR2A, NR2A, hNR2A, GRIN2A, NMDAR2A |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | GRIN2A |
|---|---|
| Synonyms | NMDAR2A |
| Function | Component of NMDA receptor complexes that function as heterotetrameric, ligand-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Channel activation requires binding of the neurotransmitter glutamate to the epsilon subunit, glycine binding to the zeta subunit, plus membrane depolarization to eliminate channel inhibition by Mg(2+) (PubMed:8768735, PubMed:26919761, PubMed:26875626, PubMed:28105280). Sensitivity to glutamate and channel kinetics depend on the subunit composition; channels containing GRIN1 and GRIN2A have lower sensitivity to glutamate and faster deactivation kinetics than channels formed by GRIN1 and GRIN2B (PubMed:26919761, PubMed:26875626). Contributes to the slow phase of excitatory postsynaptic current, long- term synaptic potentiation, and learning (By similarity). |
| Cellular Location | Cell projection, dendritic spine {ECO:0000250|UniProtKB:Q00959}. Cell membrane; Multi-pass membrane protein. Synapse {ECO:0000250|UniProtKB:P35436} Postsynaptic cell membrane {ECO:0000250|UniProtKB:Q00959}; Multi-pass membrane protein. Cytoplasmic vesicle membrane {ECO:0000250|UniProtKB:P35436}. Note=Expression at the dendrite cell membrane and at synapses is regulated by SORCS2 and the retromer complex. {ECO:0000250|UniProtKB:P35436} |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
N-methyl-D-aspartate (NMDA) receptors are a class ofionotropic glutamate-gated ion channels. These receptors have beenshown to be involved in long-term potentiation, anactivity-dependent increase in the efficiency of synaptictransmission thought to underlie certain kinds of memory andlearning. NMDA receptor channels are heteromers composed of the keyreceptor subunit NMDAR1 (GRIN1) and 1 or more of the 4 NMDAR2subunits: NMDAR2A (GRIN2A), NMDAR2B (GRIN2B), NMDAR2C (GRIN2C) andNMDAR2D (GRIN2D). Alternatively spliced transcript variantsencoding different isoforms have been found for this gene.
References
Endele, S., et al. Nat. Genet. 42(11):1021-1026(2010)Shimada, M., et al. Hum. Genet. 128(4):433-441(2010)Saus, E., et al. J Psychiatr Res 44(14):971-978(2010)Pinheiro, A.P., et al. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B (5), 1070-1080 (2010) :King, J.E., et al. Am. J. Pathol. 176(6):2819-2830(2010)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
